Cellectis to Announce Q2 2025 Financial Results on August 4

Cellectis SA ( (CLLS) ) has shared an update.

On July 28, 2025, Cellectis announced it will release its second-quarter financial results for 2025 on August 4, 2025, after the US market closes. The announcement will be followed by an investor conference call and webcast on August 5, 2025, which will cover the company’s financial performance and business updates. This event is significant for stakeholders as it provides insights into Cellectis’ operational progress and strategic direction in the biotechnology sector.

The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.

Spark’s Take on CLLS Stock

According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.

The stock score reflects strong technical momentum as the leading positive factor, supported by improving liquidity and cash flow. However, persistent losses and negative valuation metrics weigh down the score, highlighting the need for cautious optimism.

To see Spark’s full report on CLLS stock, click here.

More about Cellectis SA

Cellectis is a clinical-stage biotechnology company that leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment. Cellectis manages the entire cell and gene therapy value chain with in-house manufacturing capabilities and is listed on the Nasdaq Global Market and Euronext Growth.

Average Trading Volume: 108,317

Technical Sentiment Signal: Hold

Current Market Cap: $188.9M

For detailed information about CLLS stock, go to TipRanks’ Stock Analysis page.